Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Acquisition of Performance Share Units

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of 21,000 performance share units.

Summary

• On August 27, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, filed a Form 4.
• The filing reports the acquisition of 21,000 Performance Share Units.
• These units vested upon achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.
• Following the reported transaction, Khattar directly owns 915,217 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
• He also owns 21,000 derivative securities in the form of Performance Share Units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of performance share units suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of Performance Share Units suggests confidence in the company's future performance, as these units vest upon achievement of specific objectives.

Future Outlook

The vesting of Performance Share Units is tied to the achievement of individual performance objectives, suggesting a focus on future performance and growth.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the CEO's acquisition of performance-based equity, aligning his interests with those of the shareholders.

Stakeholder Impact

• The acquisition of performance share units aligns management's interests with those of shareholders, potentially driving long-term value creation.

Key Dates